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SHORT REPORT
Rapid degradation of an active formylglycine
generating enzyme variant leads to a late infantile
severe form of multiple sulfatase deficiency
Lars Schlotawa1,6, Karthikeyan Radhakrishnan2,3,6, Matthias Baumgartner4, Regula Schmid5,
Bernhard Schmidt3, Thomas Dierks*,2 and Jutta Ga¨rtner1
Multiple sulfatase deficiency (MSD) is a rare inborn error of metabolism affecting posttranslational activation of sulfatases
by the formylglycine generating enzyme (FGE). Due to mutations in the encoding SUMF1 gene, FGE’s catalytic capacity is
impaired resulting in reduced cellular sulfatase activities. Both, FGE protein stability and residual activity determine disease
severity and have previously been correlated with the clinical MSD phenotype. Here, we report a patient with a late infantile
severe course of disease. The patient is compound heterozygous for two so far undescribed SUMF1 mutations, c.156delC
(p.C52fsX57) and c.390A4T (p.E130D). In patient fibroblasts, mRNA of the frameshift allele is undetectable. In contrast,
the allele encoding FGE-E130D is expressed. FGE-E130D correctly localizes to the endoplasmic reticulum and has a very high
residual molecular activity in vitro (55% of wildtype FGE); however, it is rapidly degraded. Thus, despite substantial residual
enzyme activity, protein instability determines disease severity, which highlights that potential MSD treatment approaches
should target protein folding and stabilization mechanisms.
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INTRODUCTION
Multiple Sulfatase Deficiency (MSD, MIM: #272200) affects the post-
translational activation of newly synthesized sulfatases by the for-
mylglycine-generating enzyme (FGE).1 FGE is a glycoprotein
of the endoplasmatic reticulum, 341 amino acids in length as
mature enzyme, but is also secreted after N-terminal proteolytic
processing.2 The crystal structure shows a monomeric fold with two
buried calcium ions, cysteine pairs stabilizing the core domain and
two catalytic cysteines directly involved in formylglycine-generating
redox activity3–5 (Supplementary Figure S1). Mutations in the FGE-
encoding SUMF1 gene lead to instable protein and/or impaired FGE
catalytic function resulting in reduced sulfatase activities. More than
30 different SUMF1 mutations are known, most of them missense
mutations that affect stability and residual molecular activity of
mutant FGE, which both determine MSD disease severity.6,7 The
clinical phenotype includes the neonatal very severe, late infantile
(severe and mild) and rare juvenile (mild) form. MSD combines main
clinical symptoms of different single sulfatase deficiencies like
dysmorphic features, neurodegenerative course of disease and
ichthyotic skin rash. For patients with a functionally characterized
mutation, a prediction of the clinical outcome is possible.6–9 Here, we
report a patient with two novel SUMF1 mutations, one nonsense and
one missense, describe the clinical consequences and correlate this
with the molecular defects attributable to the missense mutation.
MATERIALS AND METHODS
SUMF1 mutations and enzyme activity assays
Mutational analysis of the SUMF1 gene from genomic DNA of patient
fibroblasts or leukocytes, as well as sulfatase and FGE activity assays were
performed as described earlier.10,11
Expression studies
Cell culturing of patient skin fibroblasts and HT-1080 fibrosarcoma cells as
well as stable transfection with pSB-FGE-His plasmids were described earlier.6,7
The FGE-E130D mutation was created by site-directed mutagenesis according
to the QuikChange Protocol (Stratagene, La Jolla, CA, USA) with Pfu
polymerase and complementary primer pairs (coding sequence only: FGE_
E130D-His_c 50-CATGGATGCCTATGATGTCAGTAATACTG-30).
Western blot and immunofluorescence studies
Aliquots of 50-mg cell protein, from cells of a confluent T75 cell culture flask
grown in 10ml medium for 24h, and 40ml aliquots of this medium were
analyzed by SDS–polyacrylamide gel electrophoresis and western blot using a
polyclonal FGE antibody or monoclonal His antibody (Sigma Aldrich,
Munich, Germany) as described.2 Endogenous FGE in skin fibroblasts or
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variant FGE in stably transfected HT-1080 cells was detected by indirect
immunofluorescence using a polyclonal rabbit FGE antibody as described.2
Monoclonal antibodies as organelle markers were used against PDI (Biomol,
Hamburg, Germany), LAMP1 (Abcam, Cambridge, UK) and Golgi protein
58K (Abcam, Cambridge, UK). Confocal images were taken on a Leica TCS
SP2 AOBS laser-scanning microscope and analyzed with the manufacturer’s
software (Leica, Solms, Germany).
FGE purification
HT-1080 cells stably overexpressing His-tagged wildtype or FGE-E130D were
harvested, resuspended in buffer I (20mM Tris-HCl, 40mM imidazole,
500mM sodium chloride, pH 8.0), and sonicated in presence of a protease
inhibitor cocktail (Sigma Aldrich, Munich, Germany). The cell lysate was
cleared by centrifugation at 100 000 g for 20min and loaded on a HisTrap
column (GE Healthcare, Munich, Germany) using buffer I. The column was
eluted in fractions of 1ml with buffer II (20mM Tris-HCl, 500mM sodium
chloride 500mM imidazole, pH 8.0) running a gradient from 0–100% of
buffer II in 25min on a A¨KTA system (GE Healthcare). Appropriate elution
fractions were pooled (6–8ml), and concentrated to 50ml using Amicon
centrifugation filter units (Millipore, Billerica, MA, USA). The concentrated
eluate was dialyzed against buffer III (20mM Tris-HCl, pH 8), its FGE
amount was determined and used for FGE activity assays.
Metabolic labeling and immunoprecipitation
HT-1080 cells stably expressing FGE-His or FGE-E130D-His were subjected
to metabolic labeling with 35S-methionine/cysteine and immunoprecipitation
followed by phosphorimaging and densitometric quantification (PMI System,
Biorad, Munich, Germany) as described.7
RESULTS
A patient with MSD displays a late infantile severe phenotype and
reduced sulfatase activities
The female patient was born as the second child of non-consangui-
neous parents from Switzerland. In the first months she presented
with muscular hypotonia and had a consecutive developmental
delay. She was able to sit at age 14 months; at age 20 months she
could grasp, babble, and was visually interactive. At age 22 months
progressive leg spasticity became obvious, followed by paroxysmal
tonic upward eye movements at age 25 months. At this time she
started to lose motor and visual skills. Cerebral magnetic resonance
imaging at age 27 months displayed a leukoencephalopathy pattern
as seen in metachromatic leukodystrophy. Laboratory examinations
revealed high-urine concentrations of glycosaminoglycans as well as
clearly reduced activity of three cellular sulfatases tested (Table 1).
At age 31 months she showed signs of tetraplegia, long eye lashes,
a dry and scaly skin and no more reactions to noises. At 4 years
Table 1 Residual activities of selected sulfatases in patient
fibroblasts
ASA activitya ASC activitya Gal-6-S activitya
nmol/h per mg
(þ / SD)
pmol/h per mg
(þ / SD)
nmol/h per mg
(þ / SD)
Patient Disease type % of control % of control % of control
Contr.b 66 (þ /2.3) 137 (þ /20) 7.1 (þ /0.9)
100% 100% 100%
1c LIS 14 (þ /1) 14 (þ /2) 1 (þ /0.1)
21% 10% 14%
aActivities þ / SD were assayed in total cell lysates and calculated from three independent
experiments.
bAn unaffected fibroblast cell line served as control.
c% activity in patient compared to control is highlighted in bold. Ta
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and 1 month, coarse facies and dysostosis multiplex were detected,
organomegaly was still absent. From the age of 39 months on she had
irregular breathing attacks due to intermittent central hypoventila-
tion. She died at the age of 5 years and 5 months (for a clinical
synopsis see Table 2). The course of the disease in this patient could
be classified as late infantile severe form of MSD. The early onset of
neurodegeneration in the second year of life and the disease
progression due to the manifestation of several additional clinical
symptoms throughout her life is comparable to other described late
infantile severe cases of MSD.6–8
Two new MSD causing SUMF1 mutations
In this patient we identified two so far unknown SUMF1 mutations.
c.156delC leads to a frameshift and premature stop codon
(p.C52fsX57). On the other allele, the single nucleotide exchange
c.390A4T substitutes glutamate at position 130 of FGE by aspartate.
At the mRNA level only the nucleotide exchange c.390A4T was
detectable (data not shown).
FGE-E130D: correct intracellular localization, exceptionally high
residual activity but drastically impaired intracellular stability and
no secretion
Endogenous FGE-E130D in patient fibroblasts was hardly
detectable (Supplementary Figure S2). For detailed analysis we
expressed recombinant His-tagged FGE-E130D in human HT-1080
fibrosarcoma cells. FGE-E130D was correctly localized in the endo-
plasmatic reticulum (Figure 1a). Western blot analysis (Figure 1b)
revealed that FGE-E130D was not secreted, whereas a major fraction
of wildtype FGE was secreted in a N-terminally truncated form
(38 kDa, starting at glutamate-73) due to proteolytic processing
during secretion, as described previously.2 Pulse-chase analysis by
metabolic 35S-labeling indicated a severe reduction of the intracellular
stability of FGE-E130D, such that about 90% of the protein was
degraded within 3 h (Figure 1d). Partially purified FGE-E130D
displayed a residual FGE activity of 55 þ /16% (Figure 1c). Of
note, the intracellular FGE-E130D was present in two molecular
forms, one with a molecular mass of 41 kDa, comparable to wildtype
FGE, and the other with 43–44 kDa. Endoglycosidase H treatment
converted both forms to a 39-kDa form (data not shown).
DISCUSSION
MSD is still an untreatable disease. Thus, potential treatment
approaches, and also genetic counseling, directly depend on thorough
analyses of the functional consequences of human SUMF1 mutations
on the clinical and biochemical phenotype. In a severely affected MSD
patient with the late infantile onset of disease we identified and
characterized two yet undescribed SUMF1 mutations, namely
c.156delC and c.390A4T. As no corresponding mRNA for the single
nucleotide deletion (p.C52fsX57) could be detected, probably in
consequence of nonsense mediated decay,12 the resulting sulfatase
acitivities and apparently also the clinical phenotype are due to the
missense mutation c.390A4T leading to expression of FGE-E130D
protein.
The E130D mutation severely destabilizes FGE
Missense mutations represent the majority of genetic defects in MSD.
For eight different missense mutations the instability of mutant FGE,
as predicted from the crystal structure, could be verified by stability
Figure 1 Localization, expression, activity and stability of FGE-E130D in HT-1080 cells. (a) Immunofluorescence detection of FGE (red) in stably
transfected cells indicates that FGE-E130D, like wildtype FGE, co-localizes with the endoplasmatic reticulum marker protein disulfide isomerase (PDI,
green), as shown in the merge. Untransfected cells (control) show endogenous FGE expression. (b) Western blot analysis of recombinant FGE-E130D, in
comparison to wildtype FGE. Equal amounts of total cell lysate and medium were analyzed. Due to instability (see panel D) FGE-E130D is expressed at
markedly reduced steady-state levels. The asterisk labels a specific band observed for FGE-E130D that is sensitive to glycosidase treatment (see text). (c)
Residual activity of FGE-E130D was measured after partial purification of the protein from transfected cells. Defined amounts of FGE protein (27 ng, upper
panel) were used for the assay. Measured activity is given relative to that of wildtype FGE, which was purified and incubated under identical conditions in
parallel (mean values þ / SD, n¼3). (d) Stability of FGE-E130D. After metabolic labeling, FGE protein was immunoprecipitated from cells and medium
either immediately, 1.5 or 3 h after labeling. The intensity of bands was quantified and expressed as percentage of the protein amount present at 0 h (see
lower panel). Note that about equal amounts of wildtype and mutant FGE were present at 0 h; however, FGE-E130D vanished almost completely from the
cells within three hours and was not secreted.
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and residual activity measurements.4,6,7 In FGE-E130D the aspartate-
130 side-chain is too short to position one of two calcium ions in the
coordination plane. Consequently, interactions with adjacent residues
are disturbed (Supplementary Figure S1) leading to protein destabi-
lization and most likely early degradation.13 Indeed, we could show
that FGE-E130D is unable to pass endoplasmatic reticulum quality
control, hence getting rapidly and completely degraded inside cells
without entering into secretion. Interestingly, we found expression of
FGE-E130D with two different molecular weights in all experiments
and even after purification (Figures 1b-d). Both forms were sensitive
to treatment with endoglycosidase H leading to a deglycosylated
39-kDa protein (data not shown). Details of these two alternative
glycosylation patterns remain to be elucidated.
FGE-E130D displays very high residual catalytic activity
Up to now, all structurally impaired FGE variants showed clearly
reduced specific enzyme activity.6,7 The residual catalytic activities
have been determined with purified FGE variants and reflect the true
molecular enzymatic capacity of the mutant proteins in vitro. FGE-
E130D shows a remarkable residual activity (55% compared with
wildtype). So far, this is the highest residual activity that has been
reported for a mutant FGE found in MSD. Such a high activity, if true
in vivo, would be more than enough to maintain full sulfatase
activation. However, the patient’s compromised activities of sulfatases
are in the range of no more than 10–20% of control activities, hence
indicating massive FGE deficiency. This obviously is a consequence of
the rapid degradation of FGE-E130D. Thus, protein instability is the
leading molecular factor for pathophysiology in the reported patient.
Genotype-phenotype relationship in severe late infantile MSD
The clinical course of MSD in the reported patient corresponds to the
late infantile severe form. Generally, MSD patients with high residual
FGE activity, but instable protein reveal an attenuated course of
disease.6,7 In contrast to FGE-E130D, as reported here, all other
mutant FGE proteins with high residual activity in former studies
were found to be secreted. This indicates that these mutants at least in
part were successful to pass intracellular control mechanisms of
protein folding. The specific biochemical feature of a rapidly degraded
(and hence non-secreted) FGE-E130D almost certainly contributes to
the late infantile severe phenotype of our patient, thereby highlighting
the importance of affected FGE stability and protein degradation as a
main pathophysiological cause for MSD and as a reliable indicator of
disease severity in case of high residual FGE activity. This does not
exclude that other so far undiscovered disease modifiers also influence
the clinical phenotypes of MSD patients. Our patient report
underlines that potential future therapies should aim at protein
stabilization mechanisms in particular when residual mutant
FGE activities are high.
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